Evidence map›Paper›PMID 41972845›Full record

ArticleActa oncologica (Stockholm, Sweden)2026

FOCU.SE trial: a nationwide Swedish drug repurposing protocol and research framework.

Edvard Abel, Päivi Östling, Ebba Hallersjö Hult, Katarzyna Kulbacka, Haris Babacic, Annika Baan, Ana Carneiro, Luigi De Petris, Henrik Fagman, Signe Friesland and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta oncologica (Stockholm, Sweden), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Edvard AbelDepartment of Oncology, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden; Sahlgrenska Comprehensive Cancer Centre, Department of Oncology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden. edvard.abel@vgregion.se.ORCID 0000-0002-0482-2015
Päivi ÖstlingScience for Life Laboratory (SciLifeLab), Department of Oncology-Pathology Karolinska Institutet, Stockholm. Sweden; Karolinska Comprehensive Cancer Project Unit, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0001-5501-466X
Ebba Hallersjö HultStockholm School of Economics Institute for Research, Stockholm, Sweden.ORCID 0009-0005-7247-9510
Katarzyna KulbackaSahlgrenska Comprehensive Cancer Centre, Department of Oncology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden.ORCID 0000-0002-9195-2300
Haris BabacicDepartment of Oncology and Pathology, Karolinska Institutet and SciLifeLab, Stockholm, Sweden.
Annika BaanSahlgrenska Comprehensive Cancer Centre, Department of Oncology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden.
Ana CarneiroDepartment of Oncology, Lund University Cancer Center, Institution för Clinical Sciences, Lunds University, Lund, Sweden; Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital Comprehensive Cancer Center, Skåne University Hospital, Lund, Sweden.
Luigi De PetrisCenter for Clinical Cancer Studies, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
Henrik FagmanDepartment of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Signe FrieslandDepartment of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Head-neck-, Lung-cancer and Melanoma, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.
Oskar FrisellThe Swedish Institute for Health Economics (IHE), Lund, Sweden; Department of Learning, Informatics, Management and Ethics (LIME), Karolinska Institutet, Stockholm, Sweden.
Mats HellströmDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Gabriel LindahlDepartment of Oncology and Department of Biomedical and Clinical Sciences, Linköping University, Linköping Sweden.
Katarina Steen CarlssonThe Swedish Institute for Health Economics (IHE), Lund, Sweden; Department of Clinical Sciences, Malmö, Lund University, Sweden s. Department of Research, development, education and innovation, Skåne University Hospital, Lund, Sweden.
David TamboreroDepartment of Oncology and Pathology, Karolinska Institutet and SciLifeLab, Stockholm, Sweden; Division of Pathology, Karolinska University Hospital, Stockholm, Sweden.
Antonios ValachisDepartment of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Daniel ÖhlundDepartment of Diagnostics and Intervention, and Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden.ORCID 0000-0002-5847-2778
Janne LehtiöDepartment of Oncology and Pathology, Karolinska Institutet and SciLifeLab, Stockholm, Sweden; Division of Pathology, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0002-8100-9562
Richard RosenquistDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Clinical Genetics and Genomics, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0002-0211-8788
Anders EdsjöDepartment of Clinical Genetics, Pathology and Molecular Diagnostics, Skåne University Hospital, Region Skåne, Lund, Sweden; Division of Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.ORCID 0000-0001-8783-8284
FOCU.SE trial group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41972845
PMCPMC13081547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.